Back to Search
GAUTAM BORTHAKUR, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1629177944IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
K1373(TX)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1985
Research & Publications (20)
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
PMID 19441109·Cancer·2009
8-other
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
PMID 18473351·Cancer·2008
3-trial
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
PMID 18398735·Leuk Lymphoma·2008
3-trial
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
PMID 18932257·Cancer·2008
3-trial
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
PMID 17341265·Br J Haematol·2007
8-other
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
PMID 17706165·Curr Oncol Rep·2007
6-review
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
PMID 17960607·Cancer·2007
8-other
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
PMID 16342165·Cancer·2006
3-trial
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
PMID 15239390·Int J Hematol·2004
6-review
Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood.
PMID 12871332·J Thromb Haemost·2003
8-other
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
PMID 19517473·Cancer·2009
3-trial
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
PMID 19531657·Blood·2009
8-other
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
PMID 19517462·Cancer·2009
8-other
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
PMID 19402171·Cancer·2009
8-other
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
PMID 19242494·Leukemia·2009
3-trial
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
PMID 19282457·Blood·2009
3-trial
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
PMID 19369233·Blood·2009
8-other
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
PMID 19652057·J Clin Oncol·2009
3-trial
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
PMID 19088047·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1629177944
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile